Functional transplant of a dengue virus serotype 3 (DENV3)-specific human monoclonal antibody epitope into DENV1

Journal of Virology

Volumn 90, Issue 10, 2016, Pages 5090-5097

  Messer, William B ^a   Yount, Boyd L ^b   Royal, Scott R ^b   de Alwis, Ruklanthi ^c   Widman, Douglas G ^b   Smith, Scott A ^d   Crowe, James E ^d,e   Pfaff, Jennifer M ^f   Kahle, Kristen M ^f   Doranz, Benjamin J ^f   Ibarra, Kristie D ^g   Harris, Eva ^g   de Silva, Aravinda M ^c   Baric, Ralph S ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f NONE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5J7; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; CELL CULTURE; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 3; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; ANIMAL; CHEMISTRY; CLASSIFICATION; CROSS REACTION; DENGUE VIRUS; DISEASE MODEL; GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNOLOGY; SERODIAGNOSIS; SEROTYPE; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; EPITOPES; GENETIC ENGINEERING; HUMANS; MICE; NEUTRALIZATION TESTS; SEROGROUP;

EID: 84977104059     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00155-16     Document Type: Article

References (43)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. http: //dx.doi.org/10.1038/nature12060.
2. Burke DS, Nisalak A, Johnson DE, Scott RM. 1988. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38:172-180.
3. Guzman MG, Alvarez M, Halstead SB. 2013. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 158:1445-1459. http://dx.doi.org/10.1007/s00705-013-1645-3.
4. Halstead SB, Nimmannitya S, Cohen SN. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42:311-328.
5. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38:411-419.
6. Halstead SB. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476-481. http://dx.doi.org/10.1126/science.3277268.
7. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A, CYD14 Study Group. 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:1358 -1365. http://dx.doi.org/10.1016/S0140-6736(14)61060-6.
8. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramirez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortes Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F, CYD15 Study Group. 2015. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372:113-123. http://dx.doi.org/10.1056/NEJMoa1411037.
9. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYDtetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559-1567. http://dx.doi .org/10.1016/S0140-6736(12)61428-7.
10. Rothman AL. 2011. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11:532-543. http://dx .doi.org/10.1038/nri3014.
11. Dowd KA, Pierson TC. 2011. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 411:306-315. http://dx.doi.org/10.1016/j.virol.2010.12.020.
12. Modis Y, Ogata S, Clements D, Harrison SC. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100: 6986-6991. http://dx.doi.org/10.1073/pnas.0832193100.
13. Zhang Y, Zhang W, Ogata S, Clements D, Strauss JH, Baker TS, Kuhn RJ, Rossmann MG. 2004. Conformational changes of the flavivirus E glycoprotein. Structure 12:1607-1618. http://dx.doi.org/10.1016/j.str.2004.06.019.
14. Modis Y, Ogata S, Clements D, Harrison SC. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313-319. http://dx.doi.org/10.1038/nature02165.
15. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, Jr, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 109:7439-7444. http://dx.doi.org/10.1073/pnas.1200566109.
16. Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JE, Jr, Lok SM. 2014. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med 6:358 -371. http://dx.doi.org/10.1002/emmm .201303404.
17. Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, Lok SM. 2015. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun 6:6341. http://dx.doi.org/10.1038/ncomms7341.
18. Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko VA, Leo YS, Chan SH, Smith KG, Chan AH, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JK, Ng ML, Alonso S, Fisher D, Shi PY, Hanson BJ, Lok SM, MacAry PA. 2012. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4:139ra83. http://dx.doi.org/10.1126/scitranslmed.3003888.
19. Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE, Jr, de Silva AM, Baric RS. 2015. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. mBio 6(5):e01461-15. http://dx.doi.org/10.1128/mBio.01461-15.
20. Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinsky A, Jumnainsong A, Edwards C, Quyen NT, Duangchinda T, Grimes JM, Tsai WY, Lai CY, Wang WK, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR. 2015. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16:170-177. http://dx.doi.org/10.1038/ni.3058.
21. Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney MC, Kikuti CM, Navarro Sanchez ME, Dejnirattisai W, Wongwiwat W, Haouz A, Girard-Blanc C, Petres S, Shepard WE, Despres P, Arenzana-Seisdedos F, Dussart P, Mongkolsapaya J, Screaton GR, Rey FA. 2015. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520:109-113. http://dx.doi.org/10.1038/nature14130.
22. Messer WB, Yount B, Hacker KE, Donaldson EF, Huynh JP, de Silva AM, Baric RS. 2012. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLoS Negl Trop Dis 6:e1486. http://dx.doi.org/10.1371/journal.pntd.0001486.
23. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM. 2003. Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 9:800-809. http://dx.doi.org/10.3201/eid0907.030038.
24. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E. 2004. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 78:2701-2710. http://dx.doi.org/10.1128/JVI.78.6.2701-2710.2004.
25. Diamond MS, Edgil D, Roberts TG, Lu B, Harris E. 2000. Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol 74:7814-7823. http://dx.doi.org/10.1128/JVI.74.17.7814-7823.2000.
26. Davidson E, Doranz BJ. 2014. A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology 143:13-20. http://dx.doi.org/10.1111/imm.12323.
27. Paes C, Ingalls J, Kampani K, Sulli C, Kakkar E, Murray M, Kotelnikov V, Greene TA, Rucker JB, Doranz BJ. 2009. Atomic-level mapping of antibody epitopes on a GPCR. J Am Chem Soc 131:6952-6954. http://dx .doi.org/10.1021/ja900186n.
28. Puri B, Nelson W, Porter KR, Henchal EA, Hayes CG. 1998. Complete nucleotide sequence analysis of a Western Pacific dengue-1 virus strain. Virus Genes 17:85-88. http://dx.doi.org/10.1023/A:1008009202695.
29. Repik PM, Dalrymple JM, Brandt WE, McCown JM, Russell PK. 1983. RNA fingerprinting as a method for distinguishing dengue 1 virus strains. Am J Trop Med Hyg 32:577-589.
30. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS. 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3=-untranslated region. Am J Trop Med Hyg 65:405-413.
31. van den Broek MF, Muller U, Huang S, Zinkernagel RM, Aguet M. 1995. Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev 148:5-18. http://dx.doi.org/10.1111/j.1600-065X.1995.tb00090.x.
32. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, Thompson JD. 2003. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 31:3497-3500. http://dx.doi.org/10.1093/nar/gkg500.
33. Arnold K, Bordoli L, Kopp J, Schwede T. 2006. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22:195-201. http://dx.doi.org/10.1093/bioin formatics/bti770.
34. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer F, Cassarino TG, Bertoni M, Bordoli L, Schwede T. 2014. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 42:W252-W258. http: //dx.doi.org/10.1093/nar/gku340.
35. Guex N, Peitsch MC, Schwede T. 2009. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. Electrophoresis 30(Suppl 1):S162-S173. http://dx.doi.org /10.1002/elps.200900140.
36. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. 2009. The SWISSMODEL Repository and associated resources. Nucleic Acids Res 37: D387-D392. http://dx.doi.org/10.1093/nar/gkn750.
37. Bond CS, Schuttelkopf AW. 2009. ALINE: a WYSIWYG proteinsequence alignment editor for publication-quality alignments. Acta Crystallogr D Biol Crystallogr 65:510 -512. http://dx.doi.org/10.1107/S0907444909007835.
38. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE, Jr. 2012. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 86:2665-2675. http://dx.doi.org/10.1128/JVI.06335-11.
39. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS. 2010. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6:e1000823. http://dx.doi.org/10.1371/journal.ppat.1000823.
40. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE, Jr. 2013. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. mBio 4:e00873-13. http://dx.doi.org/10.1128/mBio.00873-13.
41. Wahala WM, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, de Silva AM. 2010. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog 6:e1000821. http://dx.doi.org/10.1371/journal.ppat.1000821.
42. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6:e1000790. http://dx.doi.org/10.1371/journal.ppat .1000790.
43. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80:10208 -10217. http://dx.doi.org/10.1128/JVI.00062-06.